Armando Requejo

NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO.

NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO.

NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO.

NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO.

NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO.